ロード中...
Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential
Since the advent of immunotherapy revolutionized the treatment of metastatic renal cell carcinoma (mRCC), the attention of oncologists has been unavoidably shifted from tyrosine kinase inhibitors (TKIs) to immune checkpoint blockade, with the associated risk of listing cabozantinib as just one of ma...
保存先:
| 出版年: | Ther Adv Med Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5613858/ https://ncbi.nlm.nih.gov/pubmed/28974985 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834017724314 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|